It found that participants taking the medication semaglutide had a 20% lower risk of heart attack, stroke, or death due to cardiovascular disease, potentially benefiting millions of adults in the UK.
The study revealed that semaglutide brought about cardiovascular benefits for participants, irrespective of their starting weight or the amount of weight lost, suggesting improved outcomes even for those with mild obesity or minimal weight loss.
Prof. John Deanfield emphasized that semaglutide should be routinely prescribed for cardiovascular illnesses, indicating potential for widespread use across the UK.
[
add
]
[
|
|
...
]